The DOI matches its Crossref record; 142 of the 142 references it cites were found in a registry or an index.
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Open accessAbstract
The ErbB receptors and their cognate ligands that belong to the epidermal growth factor (EGF) family of peptides are involved in the pathogenesis of different types of carcinomas. In fact, the ErbB receptors and the EGF-like growth factors are frequently expressed in human tumors. These proteins form a complex system that regulates the proliferation and the survival of cancer cells. Therefore, ErbB receptors and their ligands might represent suitable targets for novel therapeutic approaches in human carcinomas. In this regard, different target-based agents that are directed against the ErbB receptors have been developed in the past two decades. One of these compounds, the humanized anti-ErbB-2 monoclonal antibody trastuzumab has been approved for the treatment of patients with metastatic breast cancer. The anti-EGF receptor (EGFR) antibody C225, as well as EGFR tyrosine kinase inhibitors ZD1839 and OSI-774 are currently in phase III clinical development. Several other ErbB tyrosine kinase inhibitors are in phase I/II studies. These compounds have generally been shown to have an acceptable toxicity profile and promising anti-tumor activity in heavily pretreated patients. The mechanisms of action of these compounds, as well as the potential therapeutic strategies to improve their efficacy are discussed in this review with particular regard to the combinations of anti-ErbB agents with cytotoxic drugs, or combinations of different ErbB-targeting agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Cobleigh, M. A., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,765
Epidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Self-citationAaronson, S. A. (1991) · Science · doi:10.1126/science.1659742 · Cited by 2,028
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Carpenter, G., & Cohen, S. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38983-5 · Cited by 1,622
Graus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.3.737 · Cited by 1,380
Pegram, M. D., Lipton, A., Hayes, D. F., Weber, B. L., Baselga, J. M., Tripathy, D., Baly, D., Baughman, S. A., Twaddell, T., Glaspy, J. A., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2659 · Cited by 1,067
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001
Baselga, J. M., Norton, L., Albanell, J., Kim, Y. M., & Mendelsohn, J. M. (1998) · PubMed · Cited by 996
Ciardiello, F., Caputo, R., Bianco, R., Damiano, Pomatico, G., De Placido, S., Bianco, A. R., & Tortora, G. (2000) · PubMed · Cited by 943
Current opinion in structural biology
(1992) · Current Opinion in Structural Biology · doi:10.1016/0959-440x(92)90120-v · Cited by 933
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
BindingDB (2025) · PubMed · doi:10.7270/q2dr317m · Cited by 843
Petit, A. M. V., Rak, J. W., Hung, M., Rockwell, P., Goldstein, N. I., FENDLY, B. M., & Kerbel, R. S. (1997) · Europe PMC (PubMed Central) · Cited by 836
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Shin, I., Yakes, F. M., Rojo, F., Shin, N.-Y., Bakin, A. V., Baselga, J., & Arteaga, C. L. (2002) · Nature Medicine · doi:10.1038/nm759 · Cited by 790
Goldstein, N. I., Prewett, M. C., Zuklys, K., Rockwell, P., & Mendelsohn, J. M. (1995) · PubMed · Cited by 785
Molina, M. A., Codony‐Servat, J., Albanell, J., Rojo, F., Arribas, J., & Baselga, J. M. (2001) · PubMed · Cited by 766
Proceedings of the American Association for Cancer Research.
Konings, E. J. M., van den Brandt, P. A., Saris, W. H. M., Brants, H. A. M., & Goldbohm, R. A. (2001) · Cited by 764
Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., & Kris, M. G. (2000) · PubMed · Cited by 761
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D’Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.904 · Cited by 741
Huang, S., Bock, J. M., & Harari, P. M. (1999) · PubMed · Cited by 714
Viglietto, G., Motti, M. L., Bruni, P., Melillo, R. M., D'Alessio, A., Califano, D., Vinci, F., Chiappetta, G., Tsichlis, P., Bellacosa, A., et al. (2002) · Nature Medicine · doi:10.1038/nm762 · Cited by 701
Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity.
Guy, P. M., Platko, J. V., Cantley, L. C., Cerione, R. A., & Carraway, K. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.17.8132 · Cited by 698 · cited 1×
“Reciprocally, ErbB-3 binds ligands of the HRG subfamily of peptides, and it has an impaired tyrosine kinase domain (Guy et al. 1994).”
BackgroundPegram, M., Hsu, S., Lewis, G., Pietras, R., Beryt, M., Sliwkowski, M., Coombs, D., Baly, D., Kabbinavar, F., & Slamon, D. (1999) · Oncogene · doi:10.1038/sj.onc.1202526 · Cited by 692
Prenzel, N., Fischer, O. M., Streit, S., Hart, S., & Ullrich, A. (2001) · Endocrine-related cancer · doi:10.1677/erc.0.0080011 · Cited by 673
MEMBRANE-ANCHORED GROWTH FACTORS
Massagué, J., & Pandiella, A. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.002503 · Cited by 660
Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
Sliwkowski, M. X., Ja, L., Gd, L., Te, H., FENDLY, B. M., & Fox, J. A. (1999) · PubMed · Cited by 653
Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., Placido, S. D., Bianco, A. R., & Tortora, G. (2001) · PubMed · Cited by 643
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 609
Perrotte, P., Matsumoto, T., Inoue, K., Kuniyasu, H., Eve, B. Y., Hicklin, D. J., Radinsky, R., & Dinney, C. P. (1999) · PubMed · Cited by 597
Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family
Shoyab, M., Plowman, G. D., McDonald, V. L., Bradley, J. G., & Todaro, G. J. (1989) · Science · doi:10.1126/science.2466334 · Cited by 597
Barker, A. J., Gibson, K. H., Grundy, W., Godfrey, A. A., Barlow, J. J., Healy, M. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Scarlett, L., et al. (2001) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)00344-4 · Cited by 569
Esteva, F. J., Valero, V., Booser, D., Guerra, L. T., Murray, J. L., Pusztai, L., Cristofanilli, M., Arun, B., Esmaeli, B., Fritsche, H. A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.058 · Cited by 566
Huang, S., & Harari, P. M. (2000) · PubMed · Cited by 555
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Moulder, S. L., Yakes, F. M., Muthuswamy, S. K., Bianco, R., Simpson, J. F., & Arteaga, C. L. (2001) · PubMed · Cited by 548
Seidman, A. D., Fornier, M. N., Esteva, F. J., Tan, L., Kaptain, S., Bach, A., Panageas, K. S., Arroyo, C., Valero, V., Currie, V., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2587 · Cited by 547
Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R. S., LoRusso, P. M., Rischin, D., Sauleda, S., Gee, J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.1.110 · Cited by 528
Moasser, M. M., Basso, A., Averbuch, S. D., & Rosen, N. X. (2001) · PubMed · Cited by 509
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody.
Milas, L., Mason, K. A., Hunter, N. R., et al. (2000) · PubMed · Cited by 503
Bruns, C. J., Solórzano, C. C., Harbison, M. T., Ozawa, S., Tsan, R. Z., Fan, D., Abbruzzese, J. L., Traxler, P. M., Buchdunger, E., Radinsky, R., et al. (2000) · PubMed · Cited by 498
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
All ErbB Receptors Other Than the Epidermal Growth Factor Receptor Are Endocytosis Impaired
Baulida, J., Kraus, M. H., Alimandi, M., Fiore, P. P. D., & Carpenter, G. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.9.5251 · Cited by 454
Pietras, R. J., FENDLY, B. M., Chazin, V. R., Pegram, M. D., Howell, S. B., & Slamon, D. J. (1994) · PubMed · Cited by 437
Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer, J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A., et al. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35162-6 · Cited by 434
Fan, Z., Baselga, J., Masui, H., et al. (1993) · PubMed · Cited by 431
Bruns, C. J., Harbison, M. T., Davis, D. W., Portera, C. A., Tsan, R. Z., McConkey, D. J., Evans, D. B., Abbruzzese, J. L., Hicklin, D. J., & Radinsky, R. (2000) · PubMed · Cited by 422
Lenferink, A. E. G. (1998) · The EMBO Journal · doi:10.1093/emboj/17.12.3385 · Cited by 413
Baselga, J., Norton, L., Masui, H., Pandiella, A., Coplan, K., Miller, W. H., & Mendelsohn, J. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.16.1327 · Cited by 411
Pietras, R. J., Pegram, M. D., Finn, R. S., Maneval, D. A., & Slamon, D. J. (1998) · Oncogene · doi:10.1038/sj.onc.1202132 · Cited by 386
Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4
Zhang, D., Sliwkowski, M. X., Mark, M., Frantz, G., Akita, R., Sun, Y., Hillan, K., Crowley, C., Brush, J., & Godowski, P. J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.18.9562 · Cited by 383
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
ErbB Receptor-induced Activation of Stat Transcription Factors Is Mediated by Src Tyrosine Kinases
Olayioye, M. A., Beuvink, I., Horsch, K., Daly, J. M., & Hynes, N. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17209 · Cited by 367
Muthuswamy, S. K., Gilman, M., & Brugge, J. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.10.6845 · Cited by 363
Prigent, S. A., & Gullick, W. J. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06577.x · Cited by 359
Yu, D., Jing, T., Liu, B., Yao, J., Tan, M., McDonnell, T. J., & Hung, M.-C. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80157-4 · Cited by 353
Epidermal growth factor-like modules
Campbell, I. D., & Bork, P. (1993) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(05)80111-3 · Cited by 351
Elenius, K. (1997) · The EMBO Journal · doi:10.1093/emboj/16.6.1268 · Cited by 343
Ciardiello, F., Bianco, R., Damiano, V., Lorenzo, S. D., Pepe, S., Placido, S. D., Fan, Z., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (1999) · PubMed · Cited by 332
Tyrosine kinase inhibitors: From rational design to clinical trials
Traxler, P., Bold, G., Buchdunger, E., Caravatti, G., Furet, P., Manley, P., O'Reilly, T., Wood, J., & Zimmermann, J. (2001) · Medicinal Research Reviews · doi:10.1002/med.1022 · Cited by 324
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M., & Matsuura, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1580 · Cited by 321
Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase
Harari, D., Tzahar, E., Romano, J., Shelly, M., Pierce, J., Andrews, G., & Yarden, Y. (1999) · Oncogene · doi:10.1038/sj.onc.1202631 · Cited by 318
Fontanini, G., Laurentiis, M. D., Vignati, S., Chinè, S., Lucchi, M., Silvestri, V., Mussi, A., Placido, S. D., Tortora, G., Bianco, A. R., et al. (1998) · PubMed · Cited by 306
Lane, H. A., Beuvink, I., Motoyama, A. B., Daly, J. M., Neve, R. M., & Hynes, N. E. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.9.3210-3223.2000 · Cited by 298
Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P. G. Y., Lawhorn, K., Khuri, F. R., Glisson, B. S., Myers, J. N., et al. (2001) · PubMed · Cited by 298
平田, 晃. (2004) · Medical Entomology and Zoology · Cited by 298
Xia, W., Lau, Y. K. J., Zhang, H. Z., Xiao, F. Y., Johnston, D. A., Liu, A. R., Li, L., Katz, R. L., & Hung, M. (1999) · PubMed · Cited by 295
Rusnak, D. W., Affleck, K., Cockerill, S. G., Stubberfield, C. R., Harris, R., Pagé, M., Smith, K. J., Guntrip, S. B., Carter, M. C., Shaw, R. J., et al. (2001) · PubMed · Cited by 294
Fan, Z., Lu, Y., Wu, X., & Mendelsohn, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)47026-3 · Cited by 283
Neu and its ligands: From an oncogene to neural factors
Peles, E., & Yarden, Y. (1993) · BioEssays · doi:10.1002/bies.950151207 · Cited by 279
Normanno, N., Campiglio, M., De Luca, A., Somenzi, G., Maiello, M., Ciardiello, F., Gianni, L., Salomon, D. S., & Menard, S. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf020 · Cited by 273
Self-citationAlbanell, J., Codony‐Servat, J., Rojo, F., Campo, J. M. D., Sauleda, S., Anido, J., Raspall, G., Giralt, J., Roselló, J., Nicholson, R. I., et al. (2001) · PubMed · Cited by 273
The Physiology Of Transforming Growth Factor-α
(1992) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60289-4 · Cited by 258
Motoyama, A. B., Hynes, N. E., & Lane, H. A. (2002) · PubMed · Cited by 249
Anido, J., Matar, P., Albanell, J., Guzmán, M., Rojo, F., Arribas, J., Averbuch, S. D., & Baselga, J. M. (2003) · PubMed · Cited by 247
Porębska, I., Harłozińska, A., & Bojarowski, T. (2000) · Tumor Biology · doi:10.1159/000030116 · Cited by 234
Wu, X., Rubin, M., Fan, Z., DeBlasio, T., Soos, T. J., Koff, A., & Mendelsohn, J. M. (1996) · PubMed · Cited by 228
Riese, D. J., Bermingham, Y., van Raaij, T. M., Buckley, S., Plowman, G. D., & Stern, D. F. (1996) · PubMed · Cited by 228
Inoue, K., Slaton, J. W., Perrotte, P., Davis, D. W., Bruns, C. J., Hicklin, D. J., McConkey, D. J., Sweeney, P., Radinsky, R., & Dinney, C. P. (2000) · PubMed · Cited by 225
The role of EGF-related peptides in tumor growth
Normanno, N. (2001) · Frontiers in Bioscience · doi:10.2741/a635 · Cited by 216
Self-citationSuo, Z., Risberg, B., Kalsson, M. G., Willman, K., Tierens, A., Skovlund, E., & Nesland, J. M. (2002) · The Journal of Pathology · doi:10.1002/path.1003 · Cited by 214
Anderson, N. G., Ahmad, T., Chan, K., Dobson, R., & Bundred, N. J. (2001) · International Journal of Cancer · doi:10.1002/ijc.1557 · Cited by 197
Expression of c-erbB3 protein in primary breast carcinomas
Naidu, R., Yadav, M., Nair, S., & Kutty, M. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.689 · Cited by 190
Perez-Soler, R. (2001) · Medical Entomology and Zoology · Cited by 189
Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma
Gilbertson, R. J., Perry, R., Kelly, P. J., Pearson, A. D. J., & Lunec, J. (1997) · PubMed · doi:10.25405/ncl.34590669 · Cited by 185
ErbB2/neu kinase modulates cellular p27(Kip1) and cyclin D1 through multiple signaling pathways.
Lenferink, A. E. G., Busse, D., Flanagan, W. M., Yakes, F. M., & Arteaga, C. L. (2001) · PubMed · Cited by 178
Klapper, L. N., Vaisman, N., Hurwitz, E., Pinkas-Kramarski, R., Yarden, Y., & Sela, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201029 · Cited by 174
Elenius, K., Choi, C. J., Paul, S., Santiestevan, E., Nishi, E., & Klagsbrun, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202612 · Cited by 170
Autocrine Secretion—10 Years Later
Sporn, M. B., & Roberts, A. B. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-5-408 · Cited by 167
CI-1033, a pan-erbB tyrosine kinase inhibitor
SLICHENMYER, W. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90285-4 · Cited by 165
Sarup, J. C., Johnson, R. M., King, K. L., FENDLY, B. M., Lipari, M. T., Napier, M. A., Ullrich, A., & Shepard, H. M. (1991) · PubMed · Cited by 164
Shelly, M., Pinkas-Kramarski, R., Guarino, B. C., Waterman, H., Wang, L.-M., Lyass, L., Alimandi, M., Kuo, A., Bacus, S. S., Pierce, J. H., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10496 · Cited by 161
Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.
Srinivasan, R., Gillett, C., Barnes, D. M., & Gullick, W. J. (2000) · PubMed · Cited by 158
Magné, N., Fischel, J. L., Dubreuil, A., Formento, P., Poupon, M.-F., Laurent-Puig, P., & Milano, G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600299 · Cited by 158
Myers, R. B., Srivastava, S., Oelschlager, D. K., & Grizzle, W. E. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.15.1140 · Cited by 158
Kawesha, A., Ghaneh, P., Andrén‐Sandberg, Å., Ögraed, D., Skar, R., Dawiskiba, S., Evans, J. D., Campbell, F., Lemoine, N. R., & Neoptolemos, J. P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6<469::aid-ijc1>3.0.co;2-l · Cited by 152
Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3
Chen, X., Yeung, T. K., & Wang, Z. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3731 · Cited by 151
Pinkas‐Kramarski, R., Eilam, R., Spiegler, O., Lavi, S., Liu, N., Chang, D., Wen, D., Schwartz, M., & Yarden, Y. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9387 · Cited by 148
Arteaga, C. L., Ramsey, T. T., Shawver, L. K., & Guyer, C. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.37.23247 · Cited by 144
Neu Differentiation Factor/Neuregulin Isoforms Activate Distinct Receptor Combinations
Pinkas‐Kramarski, R., Shelly, M., Glathe, S., Ratzkin, B. J., & Yarden, Y. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.32.19029 · Cited by 142
Ye, D., Mendelsohn, J. M., & Fan, Z. (1999) · Oncogene · doi:10.1038/sj.onc.1202319 · Cited by 142
Antitumor Activity of Combined Blockade of Epidermal Growth Factor Receptor and Protein Kinase A
Ciardiello, F., Damiano, V., Bianco, R., Bianco, C., Fontanini, G., Laurentiis, M. D., Placido, S. D., Mendelsohn, J. M., Bianco, A. R., & Tortora, G. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.23.1770 · Cited by 135
Self-citationMaurer, C. A., Frieß, H., Kretschmann, B., Zimmermann, A., Stauffer, A., Baer, H. U., Korc, M., & Büchler, M. W. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90444-0 · Cited by 135
The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer.
Saloman, D. S., Bianco, C., Ebert, A. D., Khan, N. I., Santis, M. D., Normanno, N., Wechselberger, C., Seno, M., Williams, K. P., Sanicola, M., et al. (2000) · Endocrine Related Cancer · doi:10.1677/erc.0.0070199 · Cited by 129
Self-citationArteaga, C. L., Winnier, A. R., Poirier, M. C., et al. (1994) · PubMed · Cited by 128
Yu, D., Liu, B., Jing, T., Sun, D., Price, J. E., Singletary, S. E., Ibrahim, N., Hortobágyi, G. N., & Hung, M. (1998) · Oncogene · doi:10.1038/sj.onc.1201729 · Cited by 127
Cohen, B. D., Kiener, P. A., Green, J. M., Foy, L., Fell, H. P., & Zhang, K. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30897 · Cited by 125
Morin, M. J. (2000) · Oncogene · doi:10.1038/sj.onc.1204102 · Cited by 120
Expression of transforming growth factor α, amphiregulin and cripto-1 in human breast carcinomas
Qi, C.-F., Liscia, D. S., Normanno, N., Merlo, G. R., Johnson, G., Gullick, W., Ciardiello, F., Saeki, T., Brandt, R., & Kim, N. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.174 · Cited by 116
Self-citationLaurence, D. J. R., & Gusterson, B. A. (1990) · Tumor Biology · doi:10.1159/000217659 · Cited by 115
Montgomery, B., Guzman, J., O’Rourke, D. M., & Stahl, W. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m000966200 · Cited by 115
Magné, N., Fischel, J., Dubreuil, A., Formento, P., Marcié, S., Jl, L., & Milano, G. A. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600103 · Cited by 114
Kumar, R., Shepard, H. M., & Mendelsohn, J. M. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.2.979 · Cited by 111
Klohs, W. D., Fry, D. W., & Kraker, A. J. (1997) · Current Opinion in Oncology · doi:10.1097/00001622-199711000-00012 · Cited by 106
Ligand and p185c-neu density govern receptorinteractions and tyrosine kinase activation.
Samanta, A., LeVea, C., Dougall, W. C., Qian, X., & GREENE, M. I. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1711 · Cited by 94
Fan, Z., Shang, B. Y., Lü, Y., Chou, J. L., & Mendelsohn, J. M. (1997) · PubMed · Cited by 93
Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski, K., Schuurhuis, D. H., Kops, G. J. P. L., Saceda, M., & Bates, S. E. (1997) · PubMed · Cited by 90
The Type 1 growth factor receptors and their ligands considered as a complex system.
Gullick, W. J. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080075 · Cited by 89
Crovello, C. S., Lai, C., Cantley, L. C., & Carraway, K. L. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26954 · Cited by 85
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
Sewell, J. M., Macleod, K. G., Ritchie, A., Smyth, J. F., & Langdon, S. P. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600058 · Cited by 79
Dixit, M., Yang, J.-L., Poirier, M. C., Price, J. O., Andrews, P. A., & Arteaga, C. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.5.365 · Cited by 74
Dw, F. (2000) · PubMed · Cited by 72
Chattopadhyay, A., & Carpenter, G. F. (2002) · Wiley eBooks · doi:10.1002/047120918x.emb0485 · Cited by 66
ErbB-4 mRNA expression is decreased in non-metastatic pancreatic cancer
Graber, H. U., Friess, H., Kaufmann, B., Willi, D., Zimmermann, A., Korc, M., & B�chler, M. W. (1999) · International Journal of Cancer · Cited by 65
D’Antonio, A., Losito, S., Pignata, S., Grassi, M., Perrone, F., Luca, A. D., Tambaro, R., Bianco, C., Gullick, W. J., Johnson, G. R., et al. (2002) · International Journal of Oncology · doi:10.3892/ijo.21.5.941 · Cited by 65
Self-citationLuca, A. D., Arra, C., D’Antonio, A., Casamassimi, A., Losito, S., Ferraro, P., Ciardiello, F., Salomon, D. S., & Normanno, N. (2000) · Oncogene · doi:10.1038/sj.onc.1203979 · Cited by 59
Self-citationDickstein, B., Wosikowski, K., & Bates, S. E. (1995) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03535-f · Cited by 57
The EGF domain: Requirements for binding to receptors of the ErbB family
van Zoelen, E. J. J., Stortelers, C., Lenferink, A. E. G., & van de Poll, M. L. M. (2000) · Vitamins and hormones · doi:10.1016/s0083-6729(00)59005-0 · Cited by 46
Brandt, R., Wong, A. M.-L., & Hynes, N. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204709 · Cited by 44
Dickstein, B., Valverius, E. M., Wosikowski, K., Saceda, M., Pearson, J. W., Martin, M. B., & Bates, S. E. (1993) · Journal of Cellular Physiology · doi:10.1002/jcp.1041570115 · Cited by 37
Effects of c-erbB2 Overexpression on the Drug Sensitivities of Normal Human Mammary Epithelial Cells
Orr, M. S., O'Connor, P. M., & Kohn, K. W. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.12.987 · Cited by 35
Type 1 growth factor receptors: an overview of recent developments
Mason, S., & Gullick, W. J. (1995) · The Breast · doi:10.1016/0960-9776(95)90022-5 · Cited by 20
Cited by
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
Epidermal growth factor receptor (EGFR) signaling in cancer
Normanno, N., De Luca, A., Bianco, C., Strizzi, L., Mancino, M., Maiello, M. R., Carotenuto, A., De Feo, G., Caponigro, F., & Salomon, D. S. (2006) · Gene · doi:10.1016/j.gene.2005.10.018 · Cited by 2,038
Self-citationSomatic Mutations of the HER2 Kinase Domain in Lung Adenocarcinomas
Shigematsu, H., Takahashi, T., Nomura, M., Majmudar, K., Suzuki, M., Lee, H., Wistuba, I. I., Fong, K. M., Toyooka, S., Shimizu, N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4235 · Cited by 678
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Normanno, N., Tejpar, S., Morgillo, F., De Luca, A., Van Cutsem, E., & Ciardiello, F. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.111 · Cited by 436
Self-citationThe role of the EGFR signaling in tumor microenvironment
De Luca, A., Carotenuto, A., Rachiglio, A., Gallo, M., Maiello, M. R., Aldinucci, D., Pinto, A., & Normanno, N. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21260 · Cited by 359
Self-citation
Metadata
- Authors
- Normanno, N., Bianco, C., De Luca, A., Maiello, M. R., & Salomon, D. S.
- Venue
- Endocrine-related cancer
- Publisher
- Bioscientifica
- Published
- 2003-03
- Volume
- 10
- Issue
- 1
- Pages
- 1-21
- ISSN
- 1351-0088 (ISSN-L)
- OpenAlex
- W2167241562
- Cited by
- 336
- References
- 142
- FWCI
- 9.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.